Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL: Who Reports Side Effects? Age, Gender & Country Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Gender Distribution

25.7%
Female
74.3%
Male

Age Information

The average age of patients reporting adverse events with EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL is 48.7 years.

Geographic Distribution

The majority of adverse event reports for EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL originate from US.

Report Summary & Outcomes

18,558
Total Reports
18,558
As Primary/Secondary Suspect
429
Deaths Reported
1,627
Hospitalizations
101
Life-Threatening
89
Disabilities

Reporting Timeline

First adverse event report: 10100610. Most recent report: 20250823. View full timeline →

More About EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL

EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL Full Profile Reports by Year Drug Interactions